



EXECUTIVE CHAMBERS
HONOLULU

DAVID Y. IGE
GOVERNOR

September 15, 2020

GOV. MSG. NO. 1132

The Honorable Ronald D. Kouchi,
President
and Members of the Senate
Thirtieth State Legislature
State Capitol, Room 409
Honolulu, Hawai'i 96813

The Honorable Scott K. Saiki,
Speaker and Members of the
House of Representatives
Thirtieth State Legislature
State Capitol, Room 431
Honolulu, Hawai'i 96813

Dear President Kouchi, Speaker Saiki, and Members of the Legislature:

This is to inform you that on September 15, 2020, the following bill was signed into law:

HB1659 HD3 SD1

RELATING TO HEALTH.
Act 027 (20)

Sincerely,

DAVID Y. IGE
Governor, State of Hawai'i

A BILL FOR AN ACT

RELATING TO HEALTH.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. Chapter 328, Hawaii Revised Statutes, is
2 amended by adding a new section to part I to be appropriately
3 designated and to read as follows:

4 "§328- Customized patient medication package. (a) A
5 pharmacy may provide a customized patient medication package to
6 any person; provided that:

7 (1) The pharmacy has obtained the consent of the patient,
8 patient's caregiver, patient's guardian, or
9 prescribing practitioner; provided that the consent
10 may be communicated in writing, orally, or by
11 electronic transmission; provided further that the
12 format of the consent shall be identified on the
13 prescription record required to be maintained under
14 section 328-17.7;

15 (2) The consent is accompanied by the patient's current
16 prescription; and



1 (3) The customized patient medication package meets the
2 requirements of section 328-16.

3 (b) As used in this section, "customized patient
4 medication package" means a package that is prepared by a
5 pharmacist for a specific patient and contains one or more
6 prescribed solid oral dosage forms."

7 SECTION 2. Section 329-14, Hawaii Revised Statutes, is
8 amended to read as follows:

9 "(b) Any of the following opiates, including their
10 isomers, esters, ethers, salts, and salts of isomers, esters,
11 and ethers, unless specifically excepted, whenever the existence
12 of these isomers, esters, ethers, and salts is possible within
13 the specific chemical designation:

- 14 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-
15 phenethyl)-4-piperidinyl]-N-phenylacetamide);
16 (2) Acetylmethadol;
17 (3) Allylprodine;
18 (4) Alphacetylmethadol (except levo-alphacetylmethadol,
19 levomethadyl acetate, or LAAM);
20 (5) Alphameprodine;
21 (6) Alphamethadol;



- 1 (7) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-
- 2 phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-
- 3 2-phenylethyl)-4-(N-propanilido) piperidine);
- 4 (8) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
- 5 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 6 (9) Benzethidine;
- 7 (10) Betacetylmethadol;
- 8 (11) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
- 9 piperidinyl]-N-phenylpropanamide);
- 10 (12) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-
- 11 phenethyl)-3-methyl-4-piperidinyl]-N-
- 12 phenylpropanamide);
- 13 (13) Betameprodine;
- 14 (14) Betamethadol;
- 15 (15) Betaprodine;
- 16 (16) Clonitazene;
- 17 (17) Dextromoramide;
- 18 (18) Diampromide;
- 19 (19) Diethylthiambutene;
- 20 (20) Difenoxin;
- 21 (21) Dimenoxadol;



- 1 (22) Dimepheptanol;
- 2 (23) Dimethylthiambutene;
- 3 (24) Dioxaphetyl butyrate;
- 4 (25) Dipipanone;
- 5 (26) Ethylmethylthiambutene;
- 6 (27) Etonitazene;
- 7 (28) Etoxeridine;
- 8 (29) Furethidine;
- 9 (30) Hydroxypethidine;
- 10 (31) Ketobemidone;
- 11 (32) Levomoramide;
- 12 (33) Levophenacylmorphane;
- 13 (34) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-
14 piperidyl]-N-phenylpropanamide);
- 15 (35) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-
16 4-piperidinyl]-N-phenylpropanamide);
- 17 (36) Morpheridine;
- 18 (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 19 (38) Noracymethadol;
- 20 (39) Norlevorphanol;
- 21 (40) Normethadone;



- 1 (41) Norpipanone;
- 2 (42) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-
3 phenethyl)-4-piperidinyl] propanamide;
- 4 (43) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine;
- 5 (44) Phenadoxone;
- 6 (45) Phenampromide;
- 7 (46) Phenomorphan;
- 8 (47) Phenoperidine;
- 9 (48) Piritramide;
- 10 (49) Proheptazine;
- 11 (50) Properidine;
- 12 (51) Propiram;
- 13 (52) Racemoramide;
- 14 (53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-
15 piperidinyl]-propanamide);
- 16 (54) Tilidine;
- 17 (55) Trimeperidine;
- 18 (56) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
19 (benzylfentanyl), its optical isomers, salts, and
20 salts of isomers;



- 1 (57) N-[1-(2-thienyl)methyl-4-piperidyl]-N-
2 phenylpropanamide (thenylfentanyl), its optical
3 isomers, salts, and salts of isomers;
- 4 (58) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,
5 (acetyl fentanyl), its optical, positional, and
6 geometric isomers, salts, and salts of isomers;
- 7 (59) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)
8 cyclohexylmethyl]benzamide), its isomers, esters,
9 ethers, salts, and salts of isomers, esters, and
10 ethers;
- 11 (60) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, its
12 isomers, esters, ethers, salts, and salts of isomers,
13 esters, and ethers (Other names: Butyryl fentanyl);
- 14 (61) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-
15 yl]-N-phenylpropionamide, its isomers, esters, ethers,
16 salts, and salts of isomers, esters, and ethers (Other
17 names: beta-hydroxythiofentanyl);
- 18 (62) N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-
19 carboxamide, its isomers, esters, ethers, salts, and
20 salts of isomers, esters, and ethers (Other names:
21 Furanyl fentanyl); [~~and~~]




- 1 (63) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
- 2 methylbenzamide, its isomers, esters, ethers, salts,
- 3 and salts of isomers, esters, and ethers (Other names:
- 4 U-47700) [-];
- 5 (64) 4-fluoroisobutyryl fentanyl or para-fluoroisobutyryl
- 6 fenranyl [N-(4-fluorophenyl)-N-(1-phenethylpiperidin-
- 7 4-yl)isobutyramide];
- 8 (65) Acryl fentanyl or acryloylfentanyl [N-(1-
- 9 phenethylpiperidin-4-yl)-N-phenylacrylamide]; and
- 10 (66) Ocfentanil [N-(2-fluorophenyl)-2-methoxy-N-(1-
- 11 phenethylpiprtidin-4-yl)acetamide]."

12 SECTION 3. Statutory material to be repealed is bracketed
13 and stricken. New statutory material is underscored.

14 SECTION 4. This Act shall take effect upon its approval.

APPROVED this 15 day of SEP, 2020




GOVERNOR OF THE STATE OF HAWAII




THE SENATE OF THE STATE OF HAWAI'I

Date: July 1, 2020
Honolulu, Hawai'i 96813

We hereby certify that the foregoing Bill this day passed Third Reading in the Senate of the Thirtieth Legislature of the State of Hawai'i, Regular Session of 2020.


President of the Senate


Clerk of the Senate

HB No. 1659, HD 3, SD 1


THE HOUSE OF REPRESENTATIVES OF THE STATE OF HAWAII

Date: July 10, 2020
Honolulu, Hawaii

We hereby certify that the above-referenced Bill on this day passed Final Reading in the House of Representatives of the Thirtieth Legislature of the State of Hawaii, Regular Session of 2020.



Scott K. Saiki
Speaker
House of Representatives



Brian L. Takeshita
Chief Clerk
House of Representatives